Thomas Dayspring/LinkedIn
Sep 15, 2026, 17:32
Thomas Dayspring: MHT for Vasomotor Symptoms May Also Offer Cardiovascular Benefits
Thomas Dayspring, Lipid Specialist, Educator at Early Medical, shared a post on LinkedIn about a recent article by Ziyuan Wang et al, published in JAMA Internal Medicine, adding:
“Important study:
MHT for the right woman is an excellent therapy – but it is not a CV or lipid-modulating therapy per se. But when used as indicated for vasomotor symptoms in peri- and early menopause it seems some CV benefit will follow.”
Title: Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms
Authors: Ziyuan Wang, Sonja A. Swanson, Maria M. Brooks, Emma Barinas-Mitchell, Marnie Bertolet, Jared W. Magnani, Rebecca C. Thurston, Samar R. El Khoudary
Other posts featuring Thomas Dayspring on Hemostasis Today.
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?